Findings from Department of Hematology and Oncology in Breast Cancer Reported (Single arm phase II study of oral vitamin B12 for the treatment of musculoskeletal symptoms associated with aromatase inhibitors in women with early stage breast ...)
By a News Reporter-Staff News Editor at Women's Health Weekly -- Research findings on Oncology - Breast Cancer are discussed in a new report. According to news reporting from Weston, Florida, by NewsRx journalists, research stated, "Breast cancer patients receiving endocrine therapy with aromatase Inhibitors (AIs) often experience musculoskeletal and joint-related side effects. The purpose of this study was to evaluate the effect of Vitamin B12 supplements on musculoskeletal symptoms such as pain and arthralgias induced by AIs and to correlate response with serum and inflammatory biomarkers."
Financial supporters for this research include Cancer Prevention and Research Institute of Texas, Texas Tech University (see also Oncology - Breast Cancer).
The news correspondents obtained a quote from the research from the Department of Hematology and Oncology, "Upon receiving approval by the Institutional Review Board (IRB), the majority of the patients consented into the study were treated at the Texas Tech Breast Care Center. Included were patients who had a diagnosis of invasive breast cancer (Stages I-III), and were experiencing significant musculoskeletal symptoms associated to AIs. Only patients with an average pain score 4, as assessed by the Brief Pain Inventory-Short Form (BPI-SF) questionnaire, were included in the study. Participants received 2500mcg of sublingual vitamin B12 daily for 90days. Assessments at baseline and at 3 months included: BPI-SF pain scores, the impact on quality of life determined by Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES), and correlative serum markers relative to baseline (a pre-post study). A total of forty-one patients were enrolled. Average pain scores were improved by 34% (P <.0001) at 3months compared to baseline. In addition, a 23% improvement in worst pain was noted (P=.0003). Analysis of the results for the FACT-ES scoring showed improvement on all scales. No significant adverse events were observed. Decrease in pain score was correlated with increased serum B12 levels. This study suggests that Vitamin B12 reduces pain and improves quality of life for patients taking AIs who experienced AI-related musculoskeletal symptoms."
According to the news reporters, the research concluded: "If confirmed in large randomized prospective trials, Vitamin B12 would be a safe and cost-effective option for the treatment of AI-related musculoskeletal symptoms."
For more information on this research see: Single arm phase II study of oral vitamin B12 for the treatment of musculoskeletal symptoms associated with aromatase inhibitors in women with early stage breast cancer. Breast Journal, 2018;24(3):260-268. Breast Journal can be contacted at: Wiley, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; Breast Journal - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1524-4741)
Our news journalists report that additional information may be obtained by contacting Z.A. Nahleh, Cleveland Clin Florida, Dept. of Hematol Oncol, Maroone Canc Center, Weston, FL 33331, United States. Additional authors for this research include R. Heydarian, C. Ochoa, A.K. Dwivedi and A. Campbell.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1111/tbj.12951. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
Keywords for this news article include: Weston, Florida, United States, North and Central America, Clinical Trials and Studies, Mixed Function Oxygenases, Enzymes and Coenzymes, Steroid Hydroxylases, Health and Medicine, Endocrine Research, Clinical Research, Oxidoreductases, Women's Health, Breast Cancer, Hemeproteins, Cytochromes, Aromatase, Oncology, Department of Hematology and Oncology.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC